Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin

Overview

RATIONALE: Alpha-lipoic acid may prevent or lessen hearing loss caused by cisplatin. PURPOSE: This randomized clinical trial is studying the effectiveness of alpha-lipoic acid in preventing hearing loss in cancer patients undergoing treatment with cisplatin.

Full Title of Study: “Prevention of Cisplatin Ototoxicity With the Antioxidant Alpha-Lipoic Acid”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: March 2011

Detailed Description

OBJECTIVES: Primary Determine the ability of alpha-lipoic acid supplementation to prevent or reduce the incidence and severity of hearing loss in cancer patients undergoing treatment with cisplatin. Secondary Determine if this drug improves the oxidative state, as measured by a malondialdehyde measurement of oxidative stress, thereby protecting the patient against ototoxic-induced hearing loss. OUTLINE: This is a placebo-controlled, double-blind, randomized, multicenter study. Patients are stratified by cancer stage and institution. Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive oral alpha-lipoic acid supplement once a day beginning 1 week before the start of cisplatin treatment and continuing for up to 1 month after the completion of cisplatin. During cisplatin treatment, patients discontinue supplement 1 day prior to the cisplatin treatment and resume daily supplements 2 days post treatment. Arm II: Patients receive oral placebo supplement once a day beginning 1 week before the start of cisplatin and continuing for up to 1 month after the completion of cisplatin. During cisplatin treatment, patients discontinue supplement 1 day prior to the cisplatin treatment and resume daily supplements 2 days post treatment. Hearing and ototoxicity are assessed at baseline, on each day of chemotherapy, and at 1 and 3 months post chemotherapy. Blood samples are collected periodically to measure malondialdehyde and alpha-lipoic acid levels. After completion of treatment with cisplatin, patients are followed for 3 months.

Interventions

  • Drug: alpha-lipoic acid
    • Supplements (1200mg once a day) or placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
  • Behavioral: Audiology
    • otoscopy, immittance screening, noise exposure questionnaire and individualized behavioral pure-tone in the convention and high-frequency ranges.
  • Biological: laboratory biomarker analysis
    • Plasma concentrations of Malondialdehyde (MDA) will be measures as an indicator of oxidative stress.
  • Drug: Placebo
    • Placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.

Arms, Groups and Cohorts

  • Experimental: Arm 1
    • Receiving alpha-lipoic acid during cisplatin treatment.
  • Placebo Comparator: Arm 2
    • Receiving placebo during cisplatin treatment

Clinical Trial Outcome Measures

Primary Measures

  • Ototoxicity Measurement
    • Time Frame: Baseline measurement occurred prior to first cisplatin treatment session. Follow-up measurements occurred up to 3 months after last cisplatin treatment.
    • Any American Speech and Hearing Association (ASHA)-significant hearing loss in the Sensitive Region for Ototoxicity frequencies between baseline measurement and any follow-up measurement. ASHA criteria are defined as 20 decibel (dB) increase at any test frequency, 10 dB increase at any two consecutive test frequencies, or loss of response where there was previously a response at any three test frequencies.

Secondary Measures

  • Malondialdehyde (MDA) Levels
    • Time Frame: Baseline measurement occurred prior to first cisplatin treatment session. Follow-up measurements occurred up to 3 months after last cisplatin treatment.
    • Computed maximum increase relative to baseline for each subject = (max MDA during treatment) – baseline MDA level.
  • Total Amount of Prescribed Cisplatin Dose Administered
    • Time Frame: cisplatin treatment period between 10 weeks and up to 16 weeks.
    • Maximum cumulative dose of cisplatin (mg/m^2) administered during the course of chemotherapy.

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of cancer – Receiving therapeutic treatment with cisplatin – Fertile patients must use effective contraception during and for 3 months after completion of study treatment – Cognitively and physically able to participate in the study – Must be able to provide reliable behavioral threshold responses (patient must meet intra-session reliability criterion of +/- 5 dB) – At least 6 months since prior treatment with cisplatin or other ototoxic medications (e.g., aminoglycoside antibiotics) – At least 6 months since prior and no concurrent radiotherapy for head and neck tumors – Concurrent radiotherapy targeted below the neck allowed – More than 1 month since prior alpha-lipoic acid supplements Exclusion Criteria:

  • No aggressive behavior as indicated in electronic chart notes – No documented dementia – No Alzheimer's disease – No severe psychosocial disorder – No active or recent history of middle ear disorder based on otoscopy, tympanometry, immittance, or notes in patient chart – No renal disease – No Meniere's disease or retrocochlear disorder based on patient report or notes in patient's chart – Not receiving treatment for diabetes mellitus – No concurrent vincristine or vinblastine – No other concurrent investigational therapy – No other concurrent antioxidants or vitamin E > 100 IU per day

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • US Department of Veterans Affairs
  • Collaborator
    • Oregon Health and Science University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Dawn L Martin, Principal Investigator, Portland VA Medical Center, Portland, OR

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.